Cargando…

Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease

BACKGROUND: Interleukin (IL)‐41, also known as Metrnl, is a novel immunomodulatory cytokine, which is involved in the pathogenesis of many inflammatory and metabolic diseases, but its role in thyroid autoimmune diseases is not clear. The aim of this study was to evaluate the serum IL‐41 levels in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Luping, Huang, Guoqing, Weng, Linjie, Xu, Jialu, Li, Yan, Cui, Wugeng, Li, Mingcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550969/
https://www.ncbi.nlm.nih.gov/pubmed/36036749
http://dx.doi.org/10.1002/jcla.24676
_version_ 1784805993355411456
author Gong, Luping
Huang, Guoqing
Weng, Linjie
Xu, Jialu
Li, Yan
Cui, Wugeng
Li, Mingcai
author_facet Gong, Luping
Huang, Guoqing
Weng, Linjie
Xu, Jialu
Li, Yan
Cui, Wugeng
Li, Mingcai
author_sort Gong, Luping
collection PubMed
description BACKGROUND: Interleukin (IL)‐41, also known as Metrnl, is a novel immunomodulatory cytokine, which is involved in the pathogenesis of many inflammatory and metabolic diseases, but its role in thyroid autoimmune diseases is not clear. The aim of this study was to evaluate the serum IL‐41 levels in patients with Graves' disease (GD) and its relationship with GD. METHODS: This study included a total of 49 GD patients and 47 age‐ and sex‐matched healthy individuals. All baseline data were obtained by physical examination. Free triiodothyronine 3 (FT3), free triiodothyronine 4 (FT4), thyroid‐stimulating hormone (TSH), anti‐thyroglobulin antibodies (TgAb), thyroid peroxidase antibody (TPOAb), and thyrotropin receptor antibody (TRAb) levels in plasma of GD patients were measured by chemiluminescence. The high‐sensitivity C‐reactive protein (CRP) and white blood cell count (WBC) were detected using automated biochemical analyzer. Serum IL‐41 levels were measured by enzyme‐linked immunosorbent assay. RESULTS: Serum IL‐41 levels in patients with GD were significantly lower than those in healthy controls (201.0 vs. 260.8 pg/mL, p < 0.05). There was a significant positive correlation between IL‐41 level and CRP (r = 0.2947, p = 0.0385) and WBC (r = 0.4104, p = 0.0034) in GD patients. CRP was positively correlated with TRAb (r = 0.2874, p = 0.0452) and TSH (r = 0.3651, p = 0.0099) levels in GD patients. CONCLUSIONS: This study demonstrates that GD patients have decreased serum IL‐41 levels, and IL‐41 plays a potential role in abnormal immune response of GD patients.
format Online
Article
Text
id pubmed-9550969
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95509692022-10-14 Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease Gong, Luping Huang, Guoqing Weng, Linjie Xu, Jialu Li, Yan Cui, Wugeng Li, Mingcai J Clin Lab Anal Research Articles BACKGROUND: Interleukin (IL)‐41, also known as Metrnl, is a novel immunomodulatory cytokine, which is involved in the pathogenesis of many inflammatory and metabolic diseases, but its role in thyroid autoimmune diseases is not clear. The aim of this study was to evaluate the serum IL‐41 levels in patients with Graves' disease (GD) and its relationship with GD. METHODS: This study included a total of 49 GD patients and 47 age‐ and sex‐matched healthy individuals. All baseline data were obtained by physical examination. Free triiodothyronine 3 (FT3), free triiodothyronine 4 (FT4), thyroid‐stimulating hormone (TSH), anti‐thyroglobulin antibodies (TgAb), thyroid peroxidase antibody (TPOAb), and thyrotropin receptor antibody (TRAb) levels in plasma of GD patients were measured by chemiluminescence. The high‐sensitivity C‐reactive protein (CRP) and white blood cell count (WBC) were detected using automated biochemical analyzer. Serum IL‐41 levels were measured by enzyme‐linked immunosorbent assay. RESULTS: Serum IL‐41 levels in patients with GD were significantly lower than those in healthy controls (201.0 vs. 260.8 pg/mL, p < 0.05). There was a significant positive correlation between IL‐41 level and CRP (r = 0.2947, p = 0.0385) and WBC (r = 0.4104, p = 0.0034) in GD patients. CRP was positively correlated with TRAb (r = 0.2874, p = 0.0452) and TSH (r = 0.3651, p = 0.0099) levels in GD patients. CONCLUSIONS: This study demonstrates that GD patients have decreased serum IL‐41 levels, and IL‐41 plays a potential role in abnormal immune response of GD patients. John Wiley and Sons Inc. 2022-08-29 /pmc/articles/PMC9550969/ /pubmed/36036749 http://dx.doi.org/10.1002/jcla.24676 Text en © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Gong, Luping
Huang, Guoqing
Weng, Linjie
Xu, Jialu
Li, Yan
Cui, Wugeng
Li, Mingcai
Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease
title Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease
title_full Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease
title_fullStr Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease
title_full_unstemmed Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease
title_short Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease
title_sort decreased serum interleukin‐41/metrnl levels in patients with graves' disease
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550969/
https://www.ncbi.nlm.nih.gov/pubmed/36036749
http://dx.doi.org/10.1002/jcla.24676
work_keys_str_mv AT gongluping decreasedseruminterleukin41metrnllevelsinpatientswithgravesdisease
AT huangguoqing decreasedseruminterleukin41metrnllevelsinpatientswithgravesdisease
AT wenglinjie decreasedseruminterleukin41metrnllevelsinpatientswithgravesdisease
AT xujialu decreasedseruminterleukin41metrnllevelsinpatientswithgravesdisease
AT liyan decreasedseruminterleukin41metrnllevelsinpatientswithgravesdisease
AT cuiwugeng decreasedseruminterleukin41metrnllevelsinpatientswithgravesdisease
AT limingcai decreasedseruminterleukin41metrnllevelsinpatientswithgravesdisease